Top Markets
#1 MON MON +2,759.42%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +44.53%
#4 eCash eCash +31.94%
#5 Siren Siren +24.14%
#6 SAFEcoin SAFEcoin +19.98%
#7 Janction Janction +18.96%
#8 PinGo PinGo +15.88%
#9 Velvet Velvet +15.84%
#10 Decred Decred +12.95%
Coin of the day
MON MON
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Clasificación en acciones #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Precio por acción
$0.30780727
Capitalización bursátil
$94.19M
Cambio (1 día)
-0.19%
Cambio (1 año)
-34.73%
País
FR
Comercio Sensorion SA (ALSEN)

Categoría

Healthcare
Ganancias de Sensorion SA (ALSEN)
Ganancias en Dec 2025 TTM: $-40.05M
Secondo gli ultimi rapporti finanziari di Sensorion SA, gli utili attuali della società sono $-40.05M. Nel 2023, la società ha registrato un utile di $-24.06M, un aumento con respecto a agli utili del 2022, che erano di $-29.06M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Sensorion SA desde 2011 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-40.05M 48.91%
2024 $-26.89M 11.77%
2023 $-24.06M -17.20%
2022 $-29.06M 40.87%
2021 $-20.63M 56.49%
2020 $-13.18M -19.26%
2019 $-16.33M 15.05%
2018 $-14.19M 22.11%
2017 $-11.62M 21.72%
2016 $-9.55M 64.80%
2015 $-5.79M 55.42%
2014 $-3.73M 64.62%
2013 $-2.26M 73.88%
2012 $-1.30M 56.52%
2011 $-832.10K 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -61,819.42%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -12,998.66%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -12,976.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -5,437.79%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.66B -4,233.76%
NL